Photodynamic treatment versus photodynamic treatment associated with systemic steroids for idiopathic choroidal neovascularisation.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 17202205.
- Also identified by PMC identifier 1954765.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To compare photodynamic therapy (PDT) with PDT associated with systemic steroids (SS) for the control of juxta/subfoveal idiopathic choroidal neovascularisation (ICNV). Patients with juxta/subfoveal ICNV were randomised and then treated. Visual gain and loss were defined as improvement in or worsening for two or more lines of best-corrected visual acuity (BCVA), respectively. Choroidal neovascularisation size after treatment was classified as "increased" and "reduced" if it was increased or reduced by >200 microm(2), respectively. 10 patients were treated with PDT, 10 with SS followed by PDT. The median follow-up time was 22 and 21 months for the "steroid+PDT group" and the "PDT group", respectively. At 1 year, in the PDT group, five patients had stable/improved BCVA, and five became worse; the mean number of PDT was 2.3; in the steroid+PDT group, all patients were stable/improved and the mean number of PDT was 1.2. The difference between the two groups was significant (p<0.05). At 1 year, the ICNV size after treatment was better in the steroid+PDT group than in the PDT group (p<0.05). The use of SS before PDT has shown better BCVA outcome than PDT alone (p<0.05), reducing the mean number of PDT applications (1.2 vs 2.3, respectively), with smaller scar size.
Medical subject headings
- Adrenal Cortex Hormones
- Choroidal Neovascularization
- Photochemotherapy
- Prednisolone